Literature DB >> 1531388

Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex.

C K Meshul1, A Janowsky, D E Casey, R K Stallbaumer, B Taylor.   

Abstract

Perforated synapses, which contain a discontinuous density along the postsynaptic membrane, can increase or decrease in numbers following various behavioral and biochemical manipulations. We have previously established that 14-day treatment with haloperidol causes an increase in the number of perforated synapses within the caudate nucleus (dorsolateral region) but not the nucleus accumbens (Meshul and Casey 1989). This effect was reversed if the animals were withdrawn from the drug for an equivalent period of time. We have now further examined the effects of haloperidol administration, which is associated with a high incidence of extrapyramidal side effects (EPS) and tardive dyskinesia (TD), and assessed the effects of clozapine, which appears to have a lower potential for inducing EPS and TD. Administration of haloperidol for 2 weeks significantly increased the percentage of perforated synapses in the caudate, but not in the nucleus accumbens or layer VI of medial prefrontal cortex (MPCx). There was an increase in specific [125I]epidepride binding to D-2 receptors in the caudate nucleus and MPCx following haloperidol. Administration of clozapine for 2 weeks did not affect the percentage of perforated synapses in any of the three dopamine (DA)-rich regions that were examined. There was an increase in specific [3H]SCH 23390 binding to D-1 receptors and in specific [125I]epidepride binding to D-2 receptors only within MPCx following clozapine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531388     DOI: 10.1007/bf02253587

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum.

Authors:  H W Berendse; H J Groenewegen
Journal:  J Comp Neurol       Date:  1990-09-08       Impact factor: 3.215

3.  Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine.

Authors:  W Kostowski; W Gumulka; A Cxlonkowski
Journal:  Brain Res       Date:  1972-12-24       Impact factor: 3.252

4.  Perforated postsynaptic densities: probable intermediates in synapse turnover.

Authors:  M Nieto-Sampedro; S F Hoff; C W Cotman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

5.  Organization of catecholamine neurons projecting to the frontal cortex in the rat.

Authors:  O Lindvall; A Björklund; I Divac
Journal:  Brain Res       Date:  1978-02-17       Impact factor: 3.252

6.  Immunocytochemical localization of GABAergic neurones at the electron microscopical level.

Authors:  C E Ribak; J E Vaughn; R P Barber
Journal:  Histochem J       Date:  1981-07

7.  Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand.

Authors:  K A Neve; R A Henningsen; J M Kinzie; T De Paulis; D E Schmidt; R M Kessler; A Janowsky
Journal:  J Pharmacol Exp Ther       Date:  1990-03       Impact factor: 4.030

8.  Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates.

Authors:  D E Casey
Journal:  Psychopharmacol Bull       Date:  1989

9.  Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats.

Authors:  F M Benes; P A Paskevich; J Davidson; V B Domesick
Journal:  Brain Res       Date:  1985-11-25       Impact factor: 3.252

10.  Haloperidol-induced plasticity of axon terminals in rat substantia nigra.

Authors:  F M Benes; P A Paskevich; V B Domesick
Journal:  Science       Date:  1983-09-02       Impact factor: 47.728

View more
  7 in total

Review 1.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

2.  Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway.

Authors:  C A Ingham; S H Hood; P Taggart; G W Arbuthnott
Journal:  J Neurosci       Date:  1998-06-15       Impact factor: 6.167

3.  Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study.

Authors:  Lesley A McCollum; Courtney K Walker; Joy K Roche; Rosalinda C Roberts
Journal:  Schizophr Bull       Date:  2015-03-27       Impact factor: 9.306

4.  Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.

Authors:  C K Meshul; O A Andreassen; C Allen; H A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

5.  Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling.

Authors:  Jianhong Li; Yin Guo; Frederick A Schroeder; Rachael M Youngs; Thomas W Schmidt; Craig Ferris; Christine Konradi; Schahram Akbarian
Journal:  J Neurochem       Date:  2004-09       Impact factor: 5.372

6.  Shape abnormalities of caudate nucleus in schizotypal personality disorder.

Authors:  James J Levitt; Martin Styner; Marc Niethammer; Sylvain Bouix; Min-Seong Koo; Martina M Voglmaier; Chandlee C Dickey; Margaret A Niznikiewicz; Ron Kikinis; Robert W McCarley; Martha E Shenton
Journal:  Schizophr Res       Date:  2009-03-27       Impact factor: 4.939

7.  GM1 ganglioside administration partially counteracts the morphological changes associated with haloperidol treatment within the dorsal striatum of the rat.

Authors:  C K Meshul; R K Stallbaumer; C Allen
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.